Essentials of Antimicrobial Stewardship

This second edition is lauched with humongous updates on topics added/revised such as: - 2023 to 2025 CLSI/EUCAST updates (500 plus corrections/updates are added with complete update on 75 plus tables in these chapters) - Newer Antimicrobials - 42 new antibiotics are discussed new in this new edition - Updates on Treatment guidelines and Dosing Regimens - New Duke's criteria 2023 - Module on interpretation for AES modification of VITEK AST - Practical Module in Validation of Antibiogram - Practical Module on Pathogen directed AMS audit 1000 plus corrections/updates are added with complete revision/correction of 300 plus tables in the book Major revision in interpretation of AST Chapter as per latest guidelines from CLSI and EUCAST incorporating several updates such as o Tier system of CLSI, update in the list of SDD and ECV o Update in the clinical breakpoints including Salmonella/Shigella breakpoint table o Update in the reporting of fosfomycin, aminoglycosides, CZA-ATM synergy o Update on AST reporting of B. cepacia, B. pseudomallei, Stenotrophomonas, A. baumannii o Update on treatment recommendations for invasive enterococcal infections Updates on Treatment guidelines and Dosing Regimens New Duke's criteria 2023 for IE Major update: A new Module on ‘Decision to be taken on VITEK-AES modifications’. Major update: A new Practical Module in Validation of Antibiogram based on general acceptable S% rules (with new exercise) Major update: Practical Module on Pathogen-directed (PD) AMS audit Updates in list of drugs in AWaRe classification Revised definitions on antimicrobial consumption (AMC) and antimicrobial use (AMU) Major updates on— fosfomycin and CZA-ATM synergy testing methods, AmpC detection methods etc. Major updates on BMQ and MIC guiding tables and selective reporting >40 newer antimicrobials have been incorporated in every chapter of Antimicrobial Section such as newer β-lactams and BLBLI, newer aminoglycosides, newer tetracyclines, newer quinolones and several novel antimicrobials. A major revision has been carried on treatment of tuberculosis chapter. Major revision on chapters on ‘Targeted therapy for GNB and GPC’.